AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poirel, L.
Right arrow Articles by Nordmann, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poirel, L.
Right arrow Articles by Nordmann, P.
Antimicrobial Agents and Chemotherapy, June 2004, p. 2277-2279, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2277-2279.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Nosocomial Outbreak of Extended-Spectrum ß-Lactamase SHV-5-Producing Isolates of Pseudomonas aeruginosa in Athens, Greece

Laurent Poirel,1 Evangelia Lebessi,2 Marisa Castro,1 Cindy Fèvre,1 Maria Foustoukou,2 and Patrice Nordmann1*

Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, 94275 Le Kremlin-Bicêtre, France,1 Department of Clinical Microbiology, P. and A. Kyriakou Children's Hospital, Athens, Greece2

Received 22 August 2003/ Returned for modification 16 November 2003/ Accepted 21 February 2004


   ABSTRACT
Top
 Abstract
Text
 References
 
Seven nonrepetitive Pseudomonas aeruginosa isolates producing the clavulanic acid-inhibited extended-spectrum ß-lactamase SHV-5 were isolated in the same hospital in Athens, Greece, from 1998 to 2002. All isolates except one were clonally related, and the blaSHV-5 gene was chromosomally located. This study underlined that this gene, which is widespread in Enterobacteriaceae in Greece, may disseminate also in P. aeruginosa.


   TEXT
Top
 Abstract
 Text
References
 
Pseudomonas aeruginosa is a common nosocomial pathogen, especially for immunocompromised patients. It exhibits intrinsic resistance to several ß-lactams and may acquire additional resistance mechanisms. Resistance to ceftazidime is due mostly to overexpression of the AmpC-type cephalosporinase (1). In addition, several acquired clavulanic acid-inhibited extended-spectrum ß-lactamases (ESBLs) have been identified in P. aeruginosa (18). The ESBL PER-1 is mostly from Turkey, whereas VEB-1 is from Southeast Asia (5, 16, 18). Another group of ESBLs, the GES/IBC-like enzymes, have been found in P. aeruginosa in France, South Africa, and Greece (18). In addition, rare TEM-type ESBLs have been reported in P. aeruginosa (TEM-4, -21, -24, and -42), and only two SHV-type ESBLs have been reported in that species, SHV-2a in France and SHV-12 in Thailand (18).

The ESBL SHV-5 was reported first in a Klebsiella pneumoniae isolate from Chile in 1989 (6). Subsequently, the blaSHV-5 gene was identified in several enterobacterial species scattered throughout the world and especially in Greece (3, 7, 17). The ß-lactamase SHV-5 confers a high level of resistance to ceftazidime and to monobactams.

The aim of our study was to analyze the spread of P. aeruginosa isolates expressing an ESBL phenotype and recovered in different units of a pediatric hospital in Athens, Greece, from 1998 to 2002. Between July 1998 and February 2002, 50 consecutive ceftazidime-resistant P. aeruginosa strains identified by using the API32GN system (bioMérieux, Marcy-l'Etoile, France) were isolated from different patients in the clinical microbiology laboratory of P. and A. Kyriakou Children's Hospital in Athens, Greece. Among these strains, seven isolates had an ESBL phenotype according to results of a double-disk synergy test performed with cefepime, ceftazidime, and ticarcillin-clavulanic acid disks on Mueller-Hinton agar plates, as described previously (10). P. aeruginosa isolates 1 to 7 were from hospitalized patients, and their clinical backgrounds are detailed in Table 1. Four out of the seven patients were colonized by the ESBL-positive P. aeruginosa isolates, whereas three of the patients had infections and received antibiotic regimens consisting of piperacillin-tazobactam (two patients) or meropenem (one patient) (Table 1). Isolates 1 to 6 were resistant to ceftazidime, cefotaxime, cefpirome, cefepime, and aztreonam. They were susceptible to ticarcillin-clavulanate, piperacillin-tazobactam, imipenem, and meropenem (Table 2). Isolate 7 exhibited a higher level of resistance for most ß-lactams. For all the strains, MICs of ceftazidime and cefotaxime were lowered by addition of clavulanate, which was consistent with ESBL expression (Table 2). In addition, all isolates were resistant to fluoroquinolones, gentamicin, amikacin, and tobramycin except for isolate 7, which remained susceptible to fosfomycin and ciprofloxacin. All isolates were susceptible to colistin, according to the guidelines of Gales et al. (2) using an agar dilution method.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Clinical features of blaSHV-5-positive P. aeruginosa isolates

 

View this table:
[in this window]
[in a new window]
  		TABLE 2. MICs of ß-lactams for P. aeruginosa isolates 1 to 6, isolate 7, and reference strain PU21

 
PCR experiments using primers specific for blaTEM, blaSHV, blaVEB-1, blaGES-1, and blaPER-1 (4) gave a positive result only for the blaSHV gene. Sequence analysis of the entire gene revealed its perfect identity with the blaSHV-5 gene.

Isoelectric focusing analysis performed as described elsewhere (14) showed that P. aeruginosa isolates expressed two ß-lactamases with pI values of 8.2 and 8.4 that likely corresponded to SHV-5 and the naturally occurring AmpC-type enzyme, respectively.

Transfer of the ceftazidime resistance marker of P. aeruginosa isolate 7 by conjugation or electroporation as described previously (13) using ciprofloxacin-resistant P. aeruginosa PU21 as the recipient strain failed. The location of the blaSHV-5 gene was determined precisely by using the endonuclease I-CeuI technique (9). Pulsed-field gel electrophoresis (PFGE) gave four DNA fragments from P. aeruginosa isolates 1 (0.5, 1.5, 1.7, and 2.2 Mb) and 7 (0.7, 1.3, 1.7, and 2.2 Mb) and also from the P. aeruginosa PU21 reference strain (0.5, 1.1, 1.9, and 2.2 Mb) (Fig. 1). The DNA probe for rRNA consisting of a 1,504-bp PCR fragment for 16S and 23S rRNA genes (4) hybridized with all the fragments of all P. aeruginosa DNAs except those of 2.2 Mb (Fig. 1). Hybridization with DNA probe internal to blaSHV-5 consisting of a 300-bp PCR fragment generated from whole-cell DNA of P. aeruginosa gave a single signal for isolate 1, suggesting that blaSHV-5 was chromosomally located (Fig. 1). Hybridization with a DNA probe for blaSHV-5 gave three signals for isolate 7, indicating that at least three copies of the blaSHV-5 gene were scattered on the chromosome of that strain (Fig. 1).



View larger version (71K):
[in this window]
[in a new window]
  		FIG. 1. (A) PFGE profiles of I-CeuI-digested whole-cell DNA of three P. aeruginosa isolates. Lane 1, P. aeruginosa isolate 1; lane 2, P. aeruginosa isolate 7; lane 3, P. aeruginosa PU21 reference strain. (B and C) Southern hybridization was performed with a specific probe for the 16S-23S rRNA gene (B) and an internal probe for the blaSHV-5 gene (C).

 
PCRs using primers annealing to blaSHV-5 and the IS26 transposase gene did not provide positive results, whereas IS26 was found to be associated with blaSHV-2a (11), and detection of the blaSHV-5 gene as part of a class 1 integron by PCR also failed (8).

The SHV-5-producing P. aeruginosa isolates were recovered in different units of the P. and A. Kyriakou Children's Hospital during a 5-year period. Thus, it was hypothesized that one clone may have persisted in that hospital. Consequently, genotypic comparison was performed in order to evaluate the clonality of the isolates. PFGE analysis performed with the restriction enzyme SpeI as described previously (5) showed that six out of the seven isolates likely corresponded to a single clone, whereas isolate 7 was not clonally related (Fig. 2) (15).



View larger version (140K):
[in this window]
[in a new window]
  		FIG. 2. PFGE patterns of SpeI-digested whole-cell DNA of eight P. aeruginosa isolates. Lane M, bacteriophage lambda DNA ladder; lanes 1 to 7, P. aeruginosa isolates 1 to 7; lane 8, P. aeruginosa PU21 reference strain.

 
The present work described ESBL-producing P. aeruginosa isolates in several hospitalization units of a pediatric hospital. ESBL production is frequently reported in Enterobacteriaceae but rarely in P. aeruginosa (18). As previously observed (13), the infected patients were at risk of acquiring P. aeruginosa infections. Two distinct clonal isolates were found, demonstrating coexistence of distinct ESBL-positive clones in the same unit. Another threatening aspect was that the same P. aeruginosa clone had been involved in nosocomial infections during a 4-year period of time, suggesting probable persistence of the isolate in the hospital environment.

Interestingly, the presence in the chromosome of a single isolate of several copies of the same ß-lactamase gene may explain in part the higher level of resistance to ß-lactams of that strain compared to others. It may indicate a probable location of the ß-lactamase gene blaSHV-5 on a transposable element, although this has not been identified.

This study represents the first description of the blaSHV-5 gene in the Pseudomonas species and it adds to the list of ESBLs identified in P. aeruginosa. While this work was in progress, an outbreak of 11 P. aeruginosa isolates producing SHV-5 was reported in Heraklion, Crete (12), which is in the vicinity of Athens.

In our study, the blaSHV-5 gene was chromosomally located and might have resulted from transfer of a blaSHV-5-positive plasmid from Enterobacteriaceae followed by its chromosomal integration (7). Finally, this study suggested that when ESBLs become very much prevalent in Enterobacteriaceae, they may become the source of acquired resistance in P. aeruginosa that may remain hidden if not systematically investigated.


   ACKNOWLEDGMENTS
 
This work was financed by a grant from the Ministère de l'Education Nationale et de la Recherche (grant UPRES, EA3539), Université Paris XI, Paris, France. L.P. is a researcher from the INSERM, France.


   FOOTNOTES
 
* Corresponding author. Mailing address: Service de Bactériologie-Virologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre cedex, France. Phone: 33-1-45-21-36-32. Fax: 33-1-45-21-63-40. E-mail: nordmann.patrice{at}bct.ap-hop-paris.fr. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Chen, H. Y., M. Yuan, and D. M. Livermore. 1995. Mechanisms of resistance to ß-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J. Med. Microbiol. 43:300-309.[Abstract]
  2. Gales, A. C., A. O. Reis, and R. N. Jones. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39:183-190.[Abstract/Free Full Text]
  3. Gianneli, D., E. Tzelepi, L. S. Tzouvelekis, A. F. Mentis, and C. Nikolopoulou. 1994. Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type ß-lactamase in Greek hospitals. Eur. J. Microbiol. Infect. Dis. 13:764-767.
  4. Girlich, D., L. Poirel, A. Leelaporn, A. Karim, C. Tribuddharat, M. Fennewald, and P. Nordmann. 2001. Molecular epidemiology of the integron-located VEB-1 extended-spectrum ß-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J. Clin. Microbiol. 39:175-182.[Abstract/Free Full Text]
  5. Girlich, D., T. Naas, A. Leelaporn, L. Poirel, M. Fennewald, and P. Nordmann. 2002. Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum ß-lactamase in Pseudomonas aeruginosa in Thailand. Clin. Infect. Dis. 34:175-182.
  6. Gutmann, L., B. Ferré, F. W. Goldstein, N. Rizk, E. Pinto-Schuster, J. F. Acar, and E. Collatz. 1989. SHV-5, a novel SHV-type ß-lactamase that hydrolyzes broad-spectrum cephalosporins and monobactams. Antimicrob. Agents Chemother. 33:951-956.[Abstract/Free Full Text]
  7. Legakis, N. J., L. S. Tzouvelekis, G. Hatzoudis, E. Tzelepi, A. Gourkou, T. L. Pitt, and A. C. Vatopoulos. 1995. Klebsiella pneumoniae infections in Greek hospitals. Dissemination of plasmids encoding an SHV-5-type beta-lactamase. J. Hosp. Infect. 31:177-187.[CrossRef][Medline]
  8. Lévesque, C., L. Piché, C. Larose, and P. H. Roy. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob. Agents Chemother. 39:185-191.[Abstract]
  9. Liu, S. L., A. Hessel, and K. E. Sanderson. 1993. Genomic mapping with I-Ceu I, an intron-encoded endonuclease specific for genes for ribosomal RNA, in Salmonella spp., Escherichia coli, and other bacteria. Proc. Natl. Acad. Sci. USA 90:6874-6878.[Abstract/Free Full Text]
  10. Luzzaro, F., E. Mantengoli, M. Perilli, G. Lombardi, V. Orlandi, A. Orsatti, G. Amicosante, G. M. Rossolini, and A. Toniolo. 2001. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum ß-lactamase. J. Clin. Microbiol. 39:1865-1870.[Abstract/Free Full Text]
  11. Naas, T., L. Philippon, L. Poirel, E. Ronco, and P. Nordmann. 1999. An SHV-derived extended-spectrum ß-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1281-1284.[Abstract/Free Full Text]
  12. Neonakis, I. K., E. V. Scoulica, S. K. Dimitriou, A. I. Gikas, and Y. J. Tselentis. 2003. Molecular epidemiology of extended-spectrum ß-lactamases produced by clinical isolates in a university hospital in Greece: detection of SHV-5 in Pseudomonas aeruginosa and prevalence of SHV-12. Microb. Drug Resist. 9:161-165.[CrossRef][Medline]
  13. Poirel, L., G. F. Weldhagen, C. De Champs, and P. Nordmann. 2002. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum ß-lactamase GES-2 in South Africa. J. Antimicrob. Chemother. 49:561-565.[Abstract/Free Full Text]
  14. Poirel, L., M. Guibert, S. Bellais, T. Naas, and P. Nordmann. 1999. Integron- and carbenicillinase-mediated reduced susceptibility to amoxicillin-clavulanic acid in isolates of multidrug-resistant Salmonella enterica serotype Typhimurium DT104 from French patients. Antimicrob. Agents Chemother. 43:1098-1104.[Abstract/Free Full Text]
  15. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.[Medline]
  16. Vahaboglu, H., R. Ozturk, H. Akbal, F. Coskunkan, A. Yaman, A. Kaygusuz, H. Lecblebicioglu, I. Balik, K. Aydin, and M. Oktun. 1997. Widespread detection of PER-1-type extended-spectrum ß-lactamase among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob. Agents Chemother. 41:2265-2269.[Abstract]
  17. Vatopoulos, A. C., A. Philippon, L. S. Tzouvelekis, Z. Komninou, and N. J. Legakis. 1990. Prevalence of a transferable SHV-5 type ß-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece. J. Antimicrob. Chemother. 26:635-648.[Abstract/Free Full Text]
  18. Weldhagen, G. F., L. Poirel, and P. Nordmann. 2003. Ambler class A extended-spectrum ß-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob. Agents Chemother. 47:2385-2392.[Free Full Text]

Antimicrobial Agents and Chemotherapy, June 2004, p. 2277-2279, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2277-2279.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poirel, L.
Right arrow Articles by Nordmann, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poirel, L.
Right arrow Articles by Nordmann, P.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS